Home › Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
 

Keywords :   


Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

2013-11-15 23:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Mercks investigational anti-PD-1 immunotherapy. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Too much of a good thing? Spain's green energy can exceed demand
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Weekly Recap: U.S. House Approves WIPPES Legislation, Drylock Holds Private Label Academy & More
More »